U.S. markets close in 6 hours 30 minutes

  • S&P 500

    4,130.68
    -49.08 (-1.17%)
     

  • Dow 30

    33,918.04
    -135.90 (-0.40%)
     

  • Nasdaq

    12,200.82
    +384.50 (+3.25%)
     

  • Russell 2000

    2,001.22
    +40.41 (+2.06%)
     

  • Crude Oil

    76.03
    +0.15 (+0.20%)
     

  • Gold

    1,891.10
    -39.70 (-2.06%)
     

  • Silver

    22.69
    -0.92 (-3.92%)
     

  • EUR/USD

    1.0852
    -0.0059 (-0.54%)
     

  • 10-Yr Bond

    3.5170
    +0.1210 (+3.56%)
     

  • GBP/USD

    1.2116
    -0.0113 (-0.92%)
     

  • USD/JPY

    130.3820
    +1.7780 (+1.38%)
     

  • BTC-USD

    23,318.89
    -569.33 (-2.38%)
     

  • CMC Crypto 200

    532.38
    -4.48 (-0.83%)
     

  • FTSE 100

    7,860.09
    +39.93 (+0.51%)
     

  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     
BREAKING:

Jobs report stuns as hiring surges in January, unemployment rate falls to 54-year low

Biogen shares jump 4.7% premarket on hopes for its Alzheimer's treatment lecanemab

Ciara Linnane
·1 min read
Biogen shares jump 4.7% premarket on hopes for its Alzheimer's treatment lecanemab

Biogen Inc. shares rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for Alzheimer's disease failed to meet its main goal. German-listed shares of MorphoSys fell 30% on the news, while Roche was down 4% in Zurich as the company said Phase 3 studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia did not meet their primary endpoint of slowing clinical decline. Biogen, which las

Continue reading

Recommended Stories